Business Standard

Thursday, December 26, 2024 | 01:18 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

China's Sinovac Covid-19 vaccine candidate appears safe for elderly: Report

Four of the world's eight vaccines that are in the third phase of trials are from China

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Premium

The potential vaccine could remain stable for up to three years in storage, Liu said, which might offer Sinovac some advantage in vaccine distribution to regions where cold-chain storage is not an option.

Reuters Beijing
Chinese firm Sinovac Biotech Ltd (SVA.O) said on Monday its coronavirus vaccine candidate appeared to be safe for older people, according to preliminary results from an early to mid-stage trial, while the immune responses triggered by the vaccine were slightly weaker than younger adults.

Health officials have been concerned about whether experimental vaccines could safely protect the elderly, whose immune systems usually react less robustly to vaccines, against the virus that has led to nearly 890,000 deaths worldwide.

Sinovac’s candidate CoronaVac did not cause severe side effects in a combined Phase 1 and Phase 2 trials launched in May involving

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in